Results 111 to 120 of about 23,348 (143)

Efficacy of pioglitazone in treatment of metabolic dysfunction-associated fatty liver disease

Al-Azhar Assiut Medical Journal
Background and aim Nonalcoholic fatty liver disease has emerged as a major public health challenge, with limited approved pharmacological therapies.
Mahmoud M. Khafagi, Hamdy M. Moustafa, Ahmed A. Ahmed, Mohamed A. Bashir, Abdelghany Aish, Amro M. Hassan   +5 more
doaj   +1 more source

Redox-dependent gating of VDAC by mitoNEET. [PDF]

, 2019
MitoNEET is an outer mitochondrial membrane protein essential for sensing and regulation of iron and reactive oxygen species (ROS) homeostasis. It is a key player in multiple human maladies including diabetes, cancer, neurodegeneration, and Parkinson's ...
Bai, Fang, Jennings, Patricia A, Lipper, Colin H, Mittler, Ron, Nechushtai, Rachel, Onuchic, José N, Roy, Susmita, Sohn, Yang-Sung, Stofleth, Jason T   +8 more
core  

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin

Diabetes, Metabolic Syndrome and Obesity, 2014
Masahiro Ohira,1 Takashi Yamaguchi,1 Atsuhito Saiki,1 Noriko Ban,1 Hidetoshi Kawana,1 Ayako Nagumo,1 Takeyoshi Murano,2 Kohji Shirai,3 Ichiro Tatsuno1 1Center for Diabetes, Endocrinology and Metabolism, 2Department of Clinical Laboratory Medicine ...
Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagumo A, Murano T, Shirai K, Tatsuno I   +8 more
doaj  

Pharmacokinetic interactions of pioglitazone [PDF]

, 2007
Pioglitazone is a thiazolidinedione compound used in the treatment of type 2 diabetes. It has been reported to be metabolised by multiple cytochrome P450 (CYP) enzymes, including CYP2C8, CYP2C9 and CYP3A4 in vitro.
Jaakkola, Tiina
core  

Risk management in the treatment of type 2 diabetes with pioglitazone

Diabetes, Metabolic Syndrome and Obesity, 2009
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors.
Giuseppe Derosa, Sibilla AT Salvadeo
doaj  

Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Pioglitazone significantly reduces the risk of stroke in people with diabetes, and in those with prediabetes, it markedly reduces the risk of stroke/myocardial infarction and new‐onset diabetes.
Fei Yuan, J. David Spence, Jean‐Eric Tarride   +2 more
doaj   +1 more source

Do TZDs increase the risk of heart failure for patients with diabetes? [PDF]

, 2005
Patients with diabetes who take thiazolidinediones (TZDs) have a higher incidence of congestive heart failure (CHF) than those who do not; the incidence of CHF is similar with the use of pioglitazone (Actos), troglitazone (Rezulin), or rosiglitazone ...
Baskin, Serena, Dodson, Sherry, Neher, Jon O.   +2 more
core  

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Vascular Health and Risk Management, 2008
Nasser MikhailEndocrinology Division, Olive View-UCLA Medical Center, David-Geffen School of Medicine, CA, USAAbstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through ...
Nasser Mikhail
doaj  

Pioglitazone

Journal of Postgraduate Medicine, 2014
S S, Jadhav, V K, Shivane, A R, Lila, T R, Bandgar, N S, Shah   +4 more
openaire   +2 more sources

Nebulized PPARγ agonists: a novel approach to augment neonatal lung maturation and injury repair in rats. [PDF]

, 2014
BackgroundBy stimulating lipofibroblast maturation, parenterally administered peroxisome proliferator-activated receptor γ (PPARγ) agonists promote lung homeostasis and injury repair in the neonatal lung.
Gong, Ming, Husain, Maleha, Husain, Sumair, Ibe, Basil, Li, Yishi, Morales, Edith, Paek, Dave, Rehan, Virender K, Sakurai, Reiko, Torday, John S   +9 more
core